Beyond SSRIs

Traditional antidepressants (SSRIs) can take weeks to work. PE-22-28 targets a different mechanism: the TREK-1 potassium channel. By selectively blocking this channel, PE-22-28 increases neuronal excitability in specific brain regions.

Research suggests this leads to rapid antidepressant effects and stimulates neurogenesis (the growth of new neurons) in the hippocampus. It offers a potential alternative for treatment-resistant depression with a mechanism distinct from serotonin or dopamine modulation.

Scientific References

  • Heurteaux C, et al. “TREK-1 channel blockers as a new class of antidepressants.” Embo Journal. 2006.
  • Mazella J, et al. “Spadin, a sortilin-derived peptide, targeting rodent TREK-1 channels: a new concept in the antidepressant drug design.” PLoS Biology. 2010.